US3807398A - Ocular implant - Google Patents
Ocular implant Download PDFInfo
- Publication number
- US3807398A US3807398A US00290376A US29037672A US3807398A US 3807398 A US3807398 A US 3807398A US 00290376 A US00290376 A US 00290376A US 29037672 A US29037672 A US 29037672A US 3807398 A US3807398 A US 3807398A
- Authority
- US
- United States
- Prior art keywords
- percent
- lens
- dry
- water
- pvp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007943 implant Substances 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 230000003287 optical effect Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 27
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 abstract description 24
- 102100026735 Coagulation factor VIII Human genes 0.000 abstract description 23
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract description 23
- 238000005520 cutting process Methods 0.000 abstract description 20
- UJKWLAZYSLJTKA-UHFFFAOYSA-N edma Chemical compound O1CCOC2=CC(CC(C)NC)=CC=C21 UJKWLAZYSLJTKA-UHFFFAOYSA-N 0.000 abstract description 15
- 239000003999 initiator Substances 0.000 abstract description 13
- 238000000227 grinding Methods 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 9
- 238000005266 casting Methods 0.000 abstract description 7
- 238000003860 storage Methods 0.000 abstract description 7
- 230000006872 improvement Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 239000004809 Teflon Substances 0.000 abstract description 3
- 229920006362 Teflon® Polymers 0.000 abstract description 3
- 230000008859 change Effects 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 239000003889 eye drop Substances 0.000 abstract description 2
- 229940012356 eye drops Drugs 0.000 abstract description 2
- 229920001903 high density polyethylene Polymers 0.000 abstract description 2
- 239000004700 high-density polyethylene Substances 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 229920002631 room-temperature vulcanizate silicone Polymers 0.000 abstract description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 16
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 11
- 230000006698 induction Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000000977 initiatory effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 230000003068 static effect Effects 0.000 description 5
- 238000007792 addition Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 238000001030 gas--liquid chromatography Methods 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920003074 plasdone C polymer Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 2
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- ZQMIGQNCOMNODD-UHFFFAOYSA-N diacetyl peroxide Chemical compound CC(=O)OOC(C)=O ZQMIGQNCOMNODD-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- UICXTANXZJJIBC-UHFFFAOYSA-N 1-(1-hydroperoxycyclohexyl)peroxycyclohexan-1-ol Chemical compound C1CCCCC1(O)OOC1(OO)CCCCC1 UICXTANXZJJIBC-UHFFFAOYSA-N 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 238000001159 Fisher's combined probability test Methods 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960000910 bethanechol Drugs 0.000 description 1
- NZUPCNDJBJXXRF-UHFFFAOYSA-O bethanechol Chemical compound C[N+](C)(C)CC(C)OC(N)=O NZUPCNDJBJXXRF-UHFFFAOYSA-O 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- BSJPKCJHTSQKHH-UHFFFAOYSA-N butan-2-yl butan-2-yloxycarbonyloxyperoxy carbonate Chemical compound CCC(C)OC(=O)OOOOC(=O)OC(C)CC BSJPKCJHTSQKHH-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940087490 dibenzyline Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- -1 hydroxypropyl Chemical class 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 1
- 229960002329 methacholine Drugs 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000011417 postcuring Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003847 radiation curing Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
Definitions
- ABSTRACT Improvements in the ODriscoll et a1 U. S. Pat. No. 3,700,761 composition consisting of regulating critical proportions of PVP, HEMA, MA, EDMA, Water and the first and second stage initiators for producing hydrophilic lens blanks from which reproducible and predictable hydrated lenses are obtained with ratios of acceptance of 95 98 percent, to dimensional standards between the grinding dry and hydrated wet states and with ratios of resisting dimensional change in wet storage of upwards of ninety five percent.
- compositions lying outside of the critical ranges of proportions provide lenses which are unpredictable (90 percent rejection) drift in size and do not provide reproducibility between dry and wet states and thereby create fitting problems.
- Critical ratios of MA to EDMA lying between 2.5/3.2 at 15 percent PVP content down to l/ 1 at 28 percent PVP content provide reproducibility and predictability dry-to-wet and the optimum ratio is 1.5/0.7 at 20 percent PVP (reagents containing less than 1 percent water). Further improvement is made in the method of casting and cutting of U. S. Patent'No.
- 3,700,761 in which there is used a disposable mold of Teflon, high-density polyethylene or of RTV Silicone material with break-away curved bottom which is discarded to provide a convex surface requiring no cutting thereby eliminating many cutting and grinding steps on the conventional hard-lens lathe.
- Water-soluble medicaments as in US. Pat. No. 3,700,761 can be added to precision-cut eye bandages by dissolving in H 0 and adding a total of 5 percent H O to HEMA or the medicament can be used in eye drops, the bandage with 5 percent added containing 65 percent H O instead of 60 percent.
- the present invention is an improvement of the initial step of the method of preparing the hygroscopic lens in the dry state and depends upon the casting of the lens after a critical induction period in a breakaway curved-bottom plastic mold in static condition from the liquid mixture of ingredients in critical porportions and under controlled temperature and inhibitor concentration conditions which prevent heat transfer through the mold so that an improved anisotropic lens is produced which has predictable and reproducible characteristics.
- This anisotropic lens of the present invention is characterized by different swelling and expansion between dry and wet states in the lateral direction and in the vertical direction but these changes are now reproducible and predictable to match diameters a substantially rigid and accurate fit to the eye without drift in diameter or slope or stifiness and to provide longtime and precision correction of the optical condition.
- the lens made by the method of the present invention is found to shape itself by evaporation forces, in an unusual manner to steepen the vault or slope of the lens closely resting on the cornea andsclera of the eye, shaping being similar to that of hard-lens memory characteristics.
- reproducibility and predictability are achieved by the critically controlled amounts of PVP, HEMA, EDMA, MA, Water and inhibitor which is used to stabilize the HEMA and which will produce a lens having 50-65 percent in the saline-stored condition.
- the lens drops in water content from 55 -65 percent down to 45-55 percent.
- the higher amount of water retained in the lenses in saline drops to the lower value in from thirty seconds to two minutes after insertion into the eye.
- This water content drop-off from about 50-65 percent occurs in most patients to a value of about 45-50 percent.
- the casting against the curved shape of a disposable mold permits a range of dry lenses for fitting eyes of all dimensions and the range is based upon a simplified manufacturing procedure, using a break-away .mold bottom eliminating the grinding of the cast surface while providing a simple number of base curves (5) and a simple number of diameters (5) to true and time-stable dimensions in x,y and z planes.
- FIG. 1 is a sectional view which shows a break-away mold with curved bottom into which the composition is cast and polymerized against a curved inner-surface which surface requires no further grinding or polishing.
- FIG. 2 is a sectional view which shows the breaking of the button from the mold by ram pressure and movement.
- FIG. 3 is an exploded view showing separation of the break-away bottom from the button.
- FIG. 4a shows the first stage of cutting on the lathe as shown in diagramatic form in FIG. 5.
- FIG. 4b shows the second stage
- FIG. 4c shows the third stage of cutting.
- FIG. 4d shows the finished lense
- FIG. 5 shows the mounting of the lense for cutting in stages 4a, 4b and 40, with a conventional hard lense lathe of the type shown in FIG. 6 and 9 of Mullen, U.S. Pat. No. 2,330,837.
- FIG. 6 shows the finished lense with the rim cut after the cutting stage in FIG. 4d, this rim cut being illustrated in FIG. 5.
- FIG. 6 shows the dimensions of rim cut lenses of the type shown in FIG. 5.
- FIG. 7' shows the mounting of the lense of FIG. 5 on the eye with space between the rim and sclera before evaporation contracts the lense.
- FIG. 8 shows lense of FIG. 7 after contractile evaporation.
- the accuracy of manufacture of the present invention is based upon the discovery that critical proportions are required of PVP, MA, EDMA, HEMA, Water with the initiator amounts used for first and second stage initiation in the Driscoll U.S. Pat. No. 3,700,761, and that initial amounts of hydroquinone stabilizer are required to assure storage stability and to give predictability and reproducibility between dry and wet states, these initial amounts permit economy, safety, and reliability in supply and in fitting.
- the example and drawings illustrate an improved method, based upon the discovery of first stage initiation which must be carried out in a preliminary induction stage at room temperature and which requires that the liquid mixture in static condition in the mold of FIG.
- This dry polymer is subjected to further high temperature polymerization, as taught in the ODriscoll Patent after the first stage without removing from the mold and this second stage is essential to impart hardness and brittleness which creates a button that can be ground to a tolerance of 0.01 millimeters and will maintain its shape after hydration regardless of the shape of eye to which it is applied.
- the improvement of the present invention controls opposite properties in the contact lens of rubberiness, rigidity, hardness for grinding, dimensional stability and reproducibility in a new and unusual manner by controlling the time for chain growth during a preliminary induction period prior to rapid first stage initiation which occurs in at least four hours at 40C in the oven and in the mold.
- HEMA All of the ingredients HEMA, EDMA, PVP, HPMA, MA, H 0 and inhibitor (HQ or MEHQ) control the chain growth with given initiators.
- HQ inhibitor
- a critical element for the achievement of storage stability of the lens in the wet state is the requirement that no more than one hundred parts per million (preferably 60 80 parts per million) of hydroquinone-type polymerizing inhibitor, used exclusively with HEMA, such as hydroquinone (H0) or mono-methyl ether of hydroquinone (MEHQ). It was unexpected to discover that more than 100 parts per million of HO inhibitor in HEMA would cause drifting, spreading and an increase in size of the diameter with decreased steepness of lenses which were placed in storage in isotonic saline for long periods of time (two weeks to six months).
- compositions in which the inhibitor content is controlled within critical limits of less than one hundred parts per million based upon the HEMA monomer can provide lenses which can be stored in the wet state for weeks or for several months or up to a year without increasing the critical dimensions of diameter and slope.
- the present disposible mold 11 with break-away curved bottom 11b is shown in FIG. 1 as being filled with the polymerizable composition 20 which hardens in static condition through the room-temperature induction stage (2 k 6 hours) of the present invention (see examples below), the first stage initiation under thermal break down of first initiator to assume the solid state in rubbery condition (40 60 C), the second stage under thermal break-down of second initiator (l10Cl/24 hours).
- lens 20 as shown in FIG. 4d is the lens ready for the radiation post curing step.
- the compositions made by the new method of bottom ejection of the buttom permit eliminating all cutting operations from the back (curved concave surface) of the lens 202 and more important, provide a superior lens which resists breakage since cutting inherently introduces microscopic scratches which act as stress points, initiating cracking and tearing. Eliminating all stress points on the inner-surfaces provides a stronger, longerwearing, more tear-resistant lens in hydrated condition.
- FIGS. 2 and 3 show break-away frangible section 11f in annular shape which serves as the means for permitting movement of dome portion 11d with the concave surface of the button.
- the ram 13 is positioned so that its diameter fits precisely under frangible positions 11f for free expulsion of the button (see FIGS. 2 and 3).
- the invention comtemplates the use of a modified form of break-away curved bottom in the mold which will have the rim cut dimension put in the mold part and for more automated manufactoring this method of casting and mold contour information is part of the present invention.
- FIGS. 7 and 8 The importance of the rim, which can be prescription ground to meet the various requirements of scleral slope encountered by precise examination or which can be molded as explained, can be seen by the comparison of views in FIGS. 7 and 8.
- the lens 20e has just been put back on the mounting chuck 15 which is carried on the lathe spindle 16 of the conventional machine in the Mullen Patent.
- This view illustrates a finishing polish step of the convex surface after this rim has been made.
- the terminology herein defining rim cut relates to both the rim cut casting or that which has been trimmed by cutting.
- FIG. 7 the lens 202 is shown in the stage just after removal from isotonic saline and being placed on the eye. Under the rim 20r of the lens, the tear fluid flows freely and contractile forces based upon evaporation of water begin their effect.
- the exposed outer surface of the lens 20c loses water from a range of 50 65% H O down to 45 50% M and the rim 20 thereby moves downwardly and inwardly gripping the sclera and thereby entrapping a liquid film of tear fluid, thereunder the contracted form is shown in FIG. 8.
- This mixing technique is identical with that in the O- Driscoll Patent, care being taken not to entrap air and to degas the mixture under vacuum and bleeding nitrogen gas back into the system.
- Table 1 illustrates the fomulations which have been completely analyzed, the EDMA, I-IEMA, MA all being done by gas-liquid chromatography, (GLC) with HQ and MEHQ being done by titration and being double checked by GLC.
- the water content was determined by Karl Fishers method. All values in the tables below are on a weight basis.
- Table l The water content of Table l is based upon testing average f e 9 s ms f asd n C, aver n 3 3.5 percent water, since the Plasdone C content varies from about to about 28 percent (spread of 2 percent) of the present composition for contact lenses, the average contribution of water in the mixture is less than 1 percent and that Table is entitled substantially dry (less than 1 percent)
- Table 2 illustrates the addition of 5 percent of water to HEMA. All water, in both tables 1 and 2, determinations are made by testing dry and before and after additions of water and all ingredients added to the mixture are tested in the same way. Suprisingly and unexpectedly the EDMA content is raised by 1 percent as a result of the addition of 5 percent of water and thus increase is reflected in Table 2 and emphasized by the notation (asterisk) after EDMA.
- the second stage initiator was benzoyl peroxide.
- This invention is limited to these initiators, e.g. the first stage are: disecondary butyl peroxy dicarbonate, cyclohexanone peroxide and acetyl peroxide.
- First and second stage initiators are used at a concentration of 0.05 to 0.15 percent by weight of the batch.
- series B and in Table 2 represent the best groups for simple corrective hydrated lens which meet percent of the connections in nearsightedness, far sightedness and minor astigmatigmatism (less than 2.0 diopters).
- the lens extends beyond the cornea, the distance beyond the limbus being from about 0.5 2.0 mm. and the overall diameter varying from about 13.5 15.5 mm. and the inner rim being beveled in a flat curve in a width of 0.30 0.70 mm., preferably 0.35 0.40 mm. the same rim is used with the plus lens.
- Center thicknesses in the minus lens in the dry state vary from 0.30 mm. to about 0.16 mm., depending upon the power. Thinner lenses are more highly corrected and these are made from Series C and G in Tables l and 2. Center thicknesses in the plus lenses vary from 0.30 mm. up to 0.45 mm., depending upon the power and the thicker lenses are the highly corrected ones which can be made from Series A, B, E or F compositions in Tables 1 and 2.
- Astigmatic lenses with minus correction can be cast ground by the hard lens technology of Feinbloom, US. Pat. No. 3,227,507, but the selection of the composition is important since the cylindrical correction may be cast into the inner or bottom surface and a special mold may be made and used with Series G and C in accordance with the elliptical shapes taught in Feinbloom.
- the strongest thin lenses which can be made are based uppm the more rubbery compositions having a higher PVP content, thus the Series C and Series G compositions would be selected, depending upon whether the patient had a dry eye to fit or the normal wet eye".
- Series G provides better fitting for the dry eye
- Series C provides better fitting for the wet eye.
- Series E G are obviously more efiective, the higher water content accommodating greater total dosages for sparingly soluble eye medicaments.
- the water soluble medicaments from ODriscoll et al, US. Pat. No. 3,700,761 can be incorporated in the HEMA by dissolving in H and by adding percent of H 0 to the HEMA; especially useful lenses are made in this manner to provide hydrated lens which contain 60 65% R 0, as against 55 60% H O when the 5% H O addition is omitted. With 5 percent added H O the lens after hydration is more spongy, and can release medication more efficiently.
- Uniquely precision reproducibility and predictability, dry to wet, and resistance to storage creep in long time saline storage (two weeks to one year) is achieved only with the narrow range of formulations of the present invention.
- the preferred ophthalmologically acceptable medicaments are know and include corticosteroids, sulfonamide, disinfectants, antiseptics, penicillin, pilocarpine, belladonna, dibenzyline, hydergine, methacholine, carbachol, bethanechol and the like.
- a sheath or a tube may be turned for encircling a blood vessel to which a slowrelease water soluble drug is administered to reduce blood pressure.
- a sheath may be encircled about a nerve bundle or about a bone and medication administered to aid in repair and bone growth (calciferol for example). Since hydration occurs in saline, the implant which is at the same osmotic pressure as body tissues and as blood contains, in the same electrolyte environment, a very precisely dosed amount of drug which can be used to produce a degree of precision in dosage not heretofore obtainable.
- fountain supplies of this type may be used with other implants.
- new compositions of the invention create new articles of commerce which are hygroscopic buttons in hard form and are cast from new and disposable molds with break-away bottoms.
- the buttons can be turned on a lathe to make new shaped products such as implants and contact lenses which are adapted to be hydrated in saline for water uptake of 50 65 percent.
- These disposable molds form hard products whose inner surfaces are free from fissures and cracks and which resist tearing by crack propogation from these fissures.
- a shaped ocular implant comprising a composition in dry form for medicament delivery which is subjected to cutting and thereafter hydrating in saline to form an implant having from 50 65% H O, said implant in dry form consisting essentially of polymerized random graft copolymer containing 67.2 to 79.3% HEMA, 14.25 to 28% PVP,0.1 to f.04% EDMA, 0.1 to 2.5% MA, from about 1.0 up to 5.0% H 0 and from 50 ppm of hydroquinone stabilizer, the composition having been polymerized with a low temperature initiator'and a high temperature initiator each in concentration of 0.05 to 0.15 percent after an induction period at 15 30C for a period of 2.5 to six hours.
- An implant as claimed in claim 1 in the form of an optical bandage hydrated to 50 65% B 0 in combination with a fountain solution of ophthalmologically acceptable medicament dissolved in saline solution.
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Eyeglasses (AREA)
Abstract
Description
Claims (2)
- 2. An implant as claimed in claim 1 in the form of an optical bandage containing an ophthalmologically acceptable medicament incorporated in the dry form of the implant.
- 3. An implant as claimed in claim 1 in the form of an optical bandage hydrated to 50 - 65% H2O in combination with a fountain solution of ophthalmologically acceptable medicament dissolved in saline solution.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00290376A US3807398A (en) | 1972-09-19 | 1972-09-19 | Ocular implant |
US00419245A US3841598A (en) | 1972-09-19 | 1973-11-27 | A mold for casting a hydrophilic contact lens blank |
US05/631,997 US4042552A (en) | 1972-09-19 | 1975-11-14 | Composition for hydrophilic lens blank and method of casting |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US00290376A US3807398A (en) | 1972-09-19 | 1972-09-19 | Ocular implant |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US41922873A Division | 1972-09-19 | 1973-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3807398A true US3807398A (en) | 1974-04-30 |
Family
ID=23115719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US00290376A Expired - Lifetime US3807398A (en) | 1972-09-19 | 1972-09-19 | Ocular implant |
Country Status (1)
Country | Link |
---|---|
US (1) | US3807398A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3894129A (en) * | 1973-03-15 | 1975-07-08 | American Optical Corp | Method of manufacture of strain free contact lenses |
US3901969A (en) * | 1973-09-10 | 1975-08-26 | Union Corp | Sustained release of methantheline |
DE2548061A1 (en) * | 1974-11-21 | 1976-06-10 | Warner Lambert Co | DIMENSIONS FOR CONTACT LENSES OR EYE BODY AND MASS PROCESSING |
US3988274A (en) * | 1974-05-27 | 1976-10-26 | Hoya Lens Co., Ltd. | Process for producing soft contact lenses |
JPS51161827U (en) * | 1975-06-18 | 1976-12-23 | ||
US4018853A (en) * | 1974-11-21 | 1977-04-19 | Warner-Lambert Company | Crosslinked, hydrophilic rods of pyrrolidone-methacrylate graft copolymers |
US4045547A (en) * | 1974-11-21 | 1977-08-30 | Warner-Lambert Company | Fabrication of soft contact lens and composition therefor |
US4054624A (en) * | 1974-11-21 | 1977-10-18 | Warner-Lambert Company | Preparing a hydrated contact lens |
US4126138A (en) * | 1974-06-14 | 1978-11-21 | Warner-Lambert Company | Soft contact lens |
US4158030A (en) * | 1977-06-24 | 1979-06-12 | Nick Stoyan | Method for making lenses from a modified polymerization product of methyl methacrylate |
US4201210A (en) * | 1976-06-22 | 1980-05-06 | The United States Of America As Represented By The Secretary Of Agriculture | Veterinary ocular ring device for sustained drug release |
US4300820A (en) * | 1978-11-06 | 1981-11-17 | The Kendall Company | Water absorptive composition |
US4395496A (en) * | 1981-11-16 | 1983-07-26 | Uco Optics, Inc. | Cured cellulose ester, method of curing same, and use thereof |
US20070074980A1 (en) * | 2005-09-02 | 2007-04-05 | Bankoski Brian R | Implant rehydration packages and methods of use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3496254A (en) * | 1964-07-02 | 1970-02-17 | Ceskoslovenska Akademie Ved | Method of manufacturing soft and flexible contact lenses |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3700761A (en) * | 1969-11-28 | 1972-10-24 | Griffin Lab Inc | Fabrication of soft plastic contact lens blank |
-
1972
- 1972-09-19 US US00290376A patent/US3807398A/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2976576A (en) * | 1956-04-24 | 1961-03-28 | Wichterle Otto | Process for producing shaped articles from three-dimensional hydrophilic high polymers |
US3496254A (en) * | 1964-07-02 | 1970-02-17 | Ceskoslovenska Akademie Ved | Method of manufacturing soft and flexible contact lenses |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598122B1 (en) * | 1969-04-01 | 1982-11-23 | ||
US3700761A (en) * | 1969-11-28 | 1972-10-24 | Griffin Lab Inc | Fabrication of soft plastic contact lens blank |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3894129A (en) * | 1973-03-15 | 1975-07-08 | American Optical Corp | Method of manufacture of strain free contact lenses |
US3901969A (en) * | 1973-09-10 | 1975-08-26 | Union Corp | Sustained release of methantheline |
US3988274A (en) * | 1974-05-27 | 1976-10-26 | Hoya Lens Co., Ltd. | Process for producing soft contact lenses |
US4126138A (en) * | 1974-06-14 | 1978-11-21 | Warner-Lambert Company | Soft contact lens |
US3978164A (en) * | 1974-11-21 | 1976-08-31 | Warner-Lambert Company | Pyrrolidone-methacrylate graft copolymers from 3-stage polymerization process |
US4018853A (en) * | 1974-11-21 | 1977-04-19 | Warner-Lambert Company | Crosslinked, hydrophilic rods of pyrrolidone-methacrylate graft copolymers |
US4045547A (en) * | 1974-11-21 | 1977-08-30 | Warner-Lambert Company | Fabrication of soft contact lens and composition therefor |
US4054624A (en) * | 1974-11-21 | 1977-10-18 | Warner-Lambert Company | Preparing a hydrated contact lens |
DE2548061A1 (en) * | 1974-11-21 | 1976-06-10 | Warner Lambert Co | DIMENSIONS FOR CONTACT LENSES OR EYE BODY AND MASS PROCESSING |
JPS51161827U (en) * | 1975-06-18 | 1976-12-23 | ||
US4201210A (en) * | 1976-06-22 | 1980-05-06 | The United States Of America As Represented By The Secretary Of Agriculture | Veterinary ocular ring device for sustained drug release |
US4158030A (en) * | 1977-06-24 | 1979-06-12 | Nick Stoyan | Method for making lenses from a modified polymerization product of methyl methacrylate |
US4300820A (en) * | 1978-11-06 | 1981-11-17 | The Kendall Company | Water absorptive composition |
US4395496A (en) * | 1981-11-16 | 1983-07-26 | Uco Optics, Inc. | Cured cellulose ester, method of curing same, and use thereof |
US20070074980A1 (en) * | 2005-09-02 | 2007-04-05 | Bankoski Brian R | Implant rehydration packages and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4042552A (en) | Composition for hydrophilic lens blank and method of casting | |
US3841598A (en) | A mold for casting a hydrophilic contact lens blank | |
US3807398A (en) | Ocular implant | |
US3700761A (en) | Fabrication of soft plastic contact lens blank | |
US4687485A (en) | Intraocular lens with leg means having compressible regions and/or color | |
US5300116A (en) | Keratoprosthesis | |
US3660545A (en) | Method of centrifugally casting thin edged corneal contact lenses | |
US5147394A (en) | High refractive index polymeric compositions suitable for use as expansile hydrogel intraocular lenses | |
SU558248A1 (en) | Combined contact lens and method of its manufacture | |
US3760807A (en) | Method of reshaping the cornea to eliminate refractive errors | |
US6713583B2 (en) | Intraocular lenses made from polymeric compositions | |
JP3068212B2 (en) | Multifocal diffractive ophthalmic lens | |
US6585768B2 (en) | Intraocular lenses and process for the producing molded-in type intraocular lenses | |
US3831604A (en) | Method of reshaping the cornea | |
US4961746A (en) | Intraocular lens with colored legs and method of making | |
ES2208304T3 (en) | PLASTIFIED WATER POLYMER WITH A HIGH REFRACTION INDEX FOR OPHTHALMOLOGICAL APPLICATIONS. | |
JP5096793B2 (en) | Polymer composition and ophthalmic lens body | |
US4971732A (en) | Method of molding an intraocular lens | |
TW201501916A (en) | Method and apparatus for encapsulating a rigid insert in a contact lens for correcting vision in astigmatic patients | |
JPH04295353A (en) | Intraocular implant and making thereof | |
CZ299094A3 (en) | Implantable ophthalmic lens, process of its production and a mould for making the same | |
US20180312619A1 (en) | Acrylic copolymer, which is hydrophobic, cross-linked and based on cinnamic alcohol, for intraocular lenses | |
US3841985A (en) | Irradiated composition for soft contact lens | |
US3816571A (en) | Fabrication of soft plastic lens | |
US4153349A (en) | Soft contact lens with thin edge |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: AO, INC. 14 MECHANIC ST., SOUTHBRIDGE, MA A CORP. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:WARNER-LAMBERT COMPANY A CORP.OF DE;REEL/FRAME:004001/0461 Effective date: 19820524 Owner name: AO, INC. 14 MECHANIC ST., A CORP. OF DE,MASSACHUSE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WARNER-LAMBERT COMPANY A CORP.OF DE;REEL/FRAME:004001/0461 Effective date: 19820524 |
|
AS | Assignment |
Owner name: WARNER-LAMBERT TECHNOLOGIES, INC., A DE CORP. Free format text: SECURITY INTEREST;ASSIGNOR:AO, INC., A DE CORP.;REEL/FRAME:004073/0046 Effective date: 19820528 Owner name: WARNER-LAMBERT CANADA, INC. Free format text: SECURITY INTEREST;ASSIGNOR:AO, INC., A DE CORP.;REEL/FRAME:004073/0046 Effective date: 19820528 |
|
AS | Assignment |
Owner name: IRVING TRUST COMPANY, ONE WALL ST, NEW YORK, N.Y. Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:AO, INC. A CORP. OF DEL.;REEL/FRAME:004073/0675 Effective date: 19820621 Owner name: IRVING TRUST COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AO, INC.;REEL/FRAME:004073/0675 Effective date: 19820621 |
|
AS | Assignment |
Owner name: CIBA-U.S., CIBA-GEIGY CORPORATION Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:AMERICAN OPTICAL CORPORATION, A CORP OF DE.;AD, INC.;REEL/FRAME:004510/0050;SIGNING DATES FROM |
|
AS | Assignment |
Owner name: CIBA VISION CORPORATION A COMPANY OF DE, GEORGI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CIBA-GEIGY CORPORATION, A NY COMPANY;REEL/FRAME:005699/0274 Effective date: 19910501 |